Literature DB >> 30283811

Pentylenetetrazole (PTZ)-induced Convulsion Assay to Determine GABAergic Defects in Caenorhabditis elegans.

Shruti Thapliyal1, Kavita Babu1.   

Abstract

Pentylenetetrazole (PTZ) is a GABAA receptor antagonist and is used to monitor presynaptic defects in the release of the inhibitory neurotransmitter GABA. PTZ is a competitive inhibitor of GABA, and prevents binding of GABA on the GABAA receptors present on the surface of muscle. In the absence of GABA binding, the excitatory to inhibitory signal ratio increases resulting in a convulsive phenotype. This assay provides a fast and reliable method to detect presynaptic defects in GABAergic synaptic transmission. The assay is based on correlating the extent of convulsions with the degree of presynaptic GABA release defects.

Entities:  

Keywords:  C. elegans; Convulsions; GABA; NMJ; PTZ; Synaptic transmission

Year:  2018        PMID: 30283811      PMCID: PMC6166856          DOI: 10.21769/BioProtoc.2989

Source DB:  PubMed          Journal:  Bio Protoc        ISSN: 2331-8325


  12 in total

1.  The structure of the ventral nerve cord of Caenorhabditis elegans.

Authors:  J G White; E Southgate; J N Thomson; S Brenner
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1976-08-10       Impact factor: 6.237

2.  Beyond the connectome: how neuromodulators shape neural circuits.

Authors:  Cornelia I Bargmann
Journal:  Bioessays       Date:  2012-03-06       Impact factor: 4.345

3.  The structure of the nervous system of the nematode Caenorhabditis elegans.

Authors:  J G White; E Southgate; J N Thomson; S Brenner
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1986-11-12       Impact factor: 6.237

Review 4.  Maintenance of C. elegans.

Authors:  Theresa Stiernagle
Journal:  WormBook       Date:  2006-02-11

Review 5.  The synaptic vesicle cycle: a cascade of protein-protein interactions.

Authors:  T C Südhof
Journal:  Nature       Date:  1995-06-22       Impact factor: 49.962

Review 6.  Neuronal substrates of complex behaviors in C. elegans.

Authors:  Mario de Bono; Andres Villu Maricq
Journal:  Annu Rev Neurosci       Date:  2005       Impact factor: 12.449

7.  Epileptic-like convulsions associated with LIS-1 in the cytoskeletal control of neurotransmitter signaling in Caenorhabditis elegans.

Authors:  Shelli N Williams; Cody J Locke; Andrea L Braden; Kim A Caldwell; Guy A Caldwell
Journal:  Hum Mol Genet       Date:  2004-07-14       Impact factor: 6.150

8.  Paradigms for pharmacological characterization of C. elegans synaptic transmission mutants.

Authors:  Cody Locke; Kalen Berry; Bwarenaba Kautu; Kyle Lee; Kim Caldwell; Guy Caldwell
Journal:  J Vis Exp       Date:  2008-08-18       Impact factor: 1.355

9.  The C-terminal of CASY-1/Calsyntenin regulates GABAergic synaptic transmission at the Caenorhabditis elegans neuromuscular junction.

Authors:  Shruti Thapliyal; Amruta Vasudevan; Yongming Dong; Jihong Bai; Sandhya P Koushika; Kavita Babu
Journal:  PLoS Genet       Date:  2018-03-12       Impact factor: 5.917

10.  Aldicarb-induced Paralysis Assay to Determine Defects in Synaptic Transmission in Caenorhabditis elegans.

Authors:  Kelly H Oh; Hongkyun Kim
Journal:  Bio Protoc       Date:  2017-07-20
View more
  2 in total

1.  Caenorhabditis elegans provides an efficient drug screening platform for GNAO1-related disorders and highlights the potential role of caffeine in controlling dyskinesia.

Authors:  Martina Di Rocco; Serena Galosi; Enrico Lanza; Federica Tosato; Davide Caprini; Viola Folli; Jennifer Friedman; Gianfranco Bocchinfuso; Alberto Martire; Elia Di Schiavi; Vincenzo Leuzzi; Simone Martinelli
Journal:  Hum Mol Genet       Date:  2022-03-21       Impact factor: 6.150

2.  Neuroligin-mediated neurodevelopmental defects are induced by mitochondrial dysfunction and prevented by lutein in C. elegans.

Authors:  Silvia Maglioni; Alfonso Schiavi; Marlen Melcher; Vanessa Brinkmann; Zhongrui Luo; Anna Laromaine; Nuno Raimundo; Joel N Meyer; Felix Distelmaier; Natascia Ventura
Journal:  Nat Commun       Date:  2022-05-12       Impact factor: 17.694

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.